ID   KS6B1_RAT               Reviewed;         525 AA.
AC   P67999; P21425;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 1.
DT   02-OCT-2024, entry version 171.
DE   RecName: Full=Ribosomal protein S6 kinase beta-1;
DE            Short=S6K-beta-1;
DE            Short=S6K1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:12183455, ECO:0000269|PubMed:8524831};
DE   AltName: Full=70 kDa ribosomal protein S6 kinase 1;
DE            Short=P70S6K1;
DE            Short=p70-S6K 1;
DE   AltName: Full=Ribosomal protein S6 kinase I;
DE   AltName: Full=p70 ribosomal S6 kinase alpha;
DE            Short=p70 S6 kinase alpha;
DE            Short=p70 S6K-alpha;
DE            Short=p70 S6KA;
GN   Name=Rps6kb1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=2236064; DOI=10.1073/pnas.87.21.8550;
RA   Banerjee P., Ahmad M.F., Grove J.R., Kozlosky C., Price D.J., Avruch J.;
RT   "Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8550-8554(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 24-525, AND PARTIAL PROTEIN SEQUENCE.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=1699226; DOI=10.1073/pnas.87.19.7365;
RA   Kozma S.C., Ferrari S., Bassand P., Siegmann M., Totty N., Thomas G.;
RT   "Cloning of the mitogen-activated S6 kinase from rat liver reveals an
RT   enzyme of the second messenger subfamily.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7365-7369(1990).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   LYS-123; SER-434; SER-441; THR-444 AND SER-447.
RX   PubMed=8524831; DOI=10.1073/pnas.92.25.11696;
RA   Cheatham L., Monfar M., Chou M.M., Blenis J.;
RT   "Structural and functional analysis of pp70S6k.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:11696-11700(1995).
RN   [4]
RP   ACTIVITY REGULATION.
RX   PubMed=9427642; DOI=10.1016/s0960-9822(98)70037-5;
RA   Alessi D.R., Kozlowski M.T., Weng Q.P., Morrice N., Avruch J.;
RT   "3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and
RT   activates the p70 S6 kinase in vivo and in vitro.";
RL   Curr. Biol. 8:69-81(1998).
RN   [5]
RP   PHOSPHORYLATION AT THR-252; SER-394; THR-412; SER-434; THR-444 AND SER-447,
RP   AND MUTAGENESIS OF LYS-123; THR-252; THR-256; SER-394 AND THR-412.
RX   PubMed=9632736; DOI=10.1074/jbc.273.26.16621;
RA   Weng Q.P., Kozlowski M., Belham C., Zhang A., Comb M.J., Avruch J.;
RT   "Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using
RT   site-specific anti-phosphopeptide antibodies.";
RL   J. Biol. Chem. 273:16621-16629(1998).
RN   [6]
RP   PHOSPHORYLATION AT THR-412 BY MTOR.
RX   PubMed=9465032; DOI=10.1073/pnas.95.4.1432;
RA   Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., Sabatini D.M.;
RT   "RAFT1 phosphorylation of the translational regulators p70 S6 kinase and
RT   4E-BP1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:1432-1437(1998).
RN   [7]
RP   FUNCTION, INTERACTION WITH NEURABIN-I, AND MUTAGENESIS OF 28-PHE--LEU-32.
RX   PubMed=9653190; DOI=10.1073/pnas.95.14.8351;
RA   Burnett P.E., Blackshaw S., Lai M.M., Qureshi I.A., Burnett A.F.,
RA   Sabatini D.M., Snyder S.H.;
RT   "Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal
RT   cytoskeleton.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:8351-8356(1998).
RN   [8]
RP   PHOSPHORYLATION AT THR-412.
RX   PubMed=11516946; DOI=10.1016/s0960-9822(01)00369-4;
RA   Belham C., Comb M.J., Avruch J.;
RT   "Identification of the NIMA family kinases NEK6/7 as regulators of the p70
RT   ribosomal S6 kinase.";
RL   Curr. Biol. 11:1155-1167(2001).
RN   [9]
RP   INTERACTION WITH RPTOR, TOS MOTIF, AND MUTAGENESIS OF PHE-28; ASP-29;
RP   ILE-30; ASP-31 AND LEU-32.
RX   PubMed=11967149; DOI=10.1016/s0960-9822(02)00762-5;
RA   Schalm S.S., Blenis J.;
RT   "Identification of a conserved motif required for mTOR signaling.";
RL   Curr. Biol. 12:632-639(2002).
RN   [10]
RP   AUTOPHOSPHORYLATION, AND CATALYTIC ACTIVITY.
RX   PubMed=12183455; DOI=10.1074/jbc.m205168200;
RA   Romanelli A., Dreisbach V.C., Blenis J.;
RT   "Characterization of phosphatidylinositol 3-kinase-dependent
RT   phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase
RT   1.";
RL   J. Biol. Chem. 277:40281-40289(2002).
RN   [11]
RP   INTERACTION WITH RPTOR, AND MUTAGENESIS OF PHE-28.
RX   PubMed=12604610; DOI=10.1074/jbc.c200665200;
RA   Nojima H., Tokunaga C., Eguchi S., Oshiro N., Hidayat S., Yoshino K.,
RA   Hara K., Tanaka N., Avruch J., Yonezawa K.;
RT   "The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR
RT   substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS)
RT   motif.";
RL   J. Biol. Chem. 278:15461-15464(2003).
RN   [12]
RP   ACETYLATION AT LYS-516.
RX   PubMed=20599721; DOI=10.1016/j.bbrc.2010.06.081;
RA   Fenton T.R., Gwalter J., Cramer R., Gout I.T.;
RT   "S6K1 is acetylated at lysine 516 in response to growth factor
RT   stimulation.";
RL   Biochem. Biophys. Res. Commun. 398:400-405(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-447 AND SER-452, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF EPRS.
RX   PubMed=28178239; DOI=10.1038/nature21380;
RA   Arif A., Terenzi F., Potdar A.A., Jia J., Sacks J., China A., Halawani D.,
RA   Vasu K., Li X., Brown J.M., Chen J., Kozma S.C., Thomas G., Fox P.L.;
RT   "EPRS is a critical mTORC1-S6K1 effector that influences adiposity in
RT   mice.";
RL   Nature 542:357-361(2017).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of mTOR
CC       signaling in response to growth factors and nutrients to promote cell
CC       proliferation, cell growth and cell cycle progression (PubMed:8524831).
CC       Regulates protein synthesis through phosphorylation of EIF4B, RPS6 and
CC       EEF2K, and contributes to cell survival by repressing the pro-apoptotic
CC       function of BAD (By similarity). Under conditions of nutrient
CC       depletion, the inactive form associates with the EIF3 translation
CC       initiation complex (By similarity). Upon mitogenic stimulation,
CC       phosphorylation by the mechanistic target of rapamycin complex 1
CC       (mTORC1) leads to dissociation from the EIF3 complex and activation (By
CC       similarity). The active form then phosphorylates and activates several
CC       substrates in the pre-initiation complex, including the EIF2B complex
CC       and the cap-binding complex component EIF4B (By similarity). Also
CC       controls translation initiation by phosphorylating a negative regulator
CC       of EIF4A, PDCD4, targeting it for ubiquitination and subsequent
CC       proteolysis (By similarity). Promotes initiation of the pioneer round
CC       of protein synthesis by phosphorylating POLDIP3/SKAR (By similarity).
CC       In response to IGF1, activates translation elongation by
CC       phosphorylating EEF2 kinase (EEF2K), which leads to its inhibition and
CC       thus activation of EEF2 (By similarity). Also plays a role in feedback
CC       regulation of mTORC2 by mTORC1 by phosphorylating RICTOR, resulting in
CC       the inhibition of mTORC2 and AKT1 signaling (By similarity). Also
CC       involved in feedback regulation of mTORC1 and mTORC2 by phosphorylating
CC       DEPTOR (By similarity). Mediates cell survival by phosphorylating the
CC       pro-apoptotic protein BAD and suppressing its pro-apoptotic function
CC       (By similarity). Phosphorylates mitochondrial URI1 leading to
CC       dissociation of a URI1-PPP1CC complex (By similarity). The free
CC       mitochondrial PPP1CC can then dephosphorylate RPS6KB1 at Thr-412, which
CC       is proposed to be a negative feedback mechanism for the RPS6KB1 anti-
CC       apoptotic function (By similarity). Mediates TNF-alpha-induced insulin
CC       resistance by phosphorylating IRS1 at multiple serine residues,
CC       resulting in accelerated degradation of IRS1 (By similarity). In cells
CC       lacking functional TSC1-2 complex, constitutively phosphorylates and
CC       inhibits GSK3B (By similarity). May be involved in cytoskeletal
CC       rearrangement through binding to neurabin (PubMed:9653190).
CC       Phosphorylates and activates the pyrimidine biosynthesis enzyme CAD,
CC       downstream of MTOR (By similarity). Following activation by mTORC1,
CC       phosphorylates EPRS and thereby plays a key role in fatty acid uptake
CC       by adipocytes and also most probably in interferon-gamma-induced
CC       translation inhibition (PubMed:28178239).
CC       {ECO:0000250|UniProtKB:P23443, ECO:0000250|UniProtKB:Q8BSK8,
CC       ECO:0000269|PubMed:28178239, ECO:0000269|PubMed:8524831,
CC       ECO:0000269|PubMed:9653190}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:12183455, ECO:0000269|PubMed:8524831};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:12183455,
CC         ECO:0000269|PubMed:8524831};
CC   -!- ACTIVITY REGULATION: Activation requires multiple phosphorylation
CC       events on serine/threonine residues. Activation appears to be first
CC       mediated by phosphorylation of multiple sites in the autoinhibitory
CC       domain, which facilitates phosphorylation at Thr-412, disrupting the
CC       autoinhibitory mechanism and allowing phosphorylation of Thr-252 by
CC       PDPK1. The active conformation of the kinase is believed to be
CC       stabilized by a mechanism involving three conserved phosphorylation
CC       sites located in the kinase domain activation loop (Thr-252) and in the
CC       AGC-kinase C-terminal domain (Ser-394 in the middle of the tail/linker
CC       region and Thr-412 within a hydrophobic motif at its end). Activated by
CC       mTORC1; isoform Alpha I and isoform Alpha II are sensitive to
CC       rapamycin, which inhibits activating phosphorylation at Thr-412.
CC       Activated by PDPK1 (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with PPP1R9A/neurabin-1 (PubMed:9653190). Interacts
CC       with RPTOR (PubMed:11967149, PubMed:12604610). Interacts with IRS1 (By
CC       similarity). Interacts with EIF3B and EIF3C (By similarity). Interacts
CC       with POLDIP3 (By similarity). Interacts with TRAF4 (By similarity).
CC       Interacts (via N-terminus) with IER5 (By similarity).
CC       {ECO:0000250|UniProtKB:P23443, ECO:0000269|PubMed:11967149,
CC       ECO:0000269|PubMed:12604610, ECO:0000269|PubMed:9653190}.
CC   -!- INTERACTION:
CC       P67999; O35867: Ppp1r9a; NbExp=4; IntAct=EBI-2639458, EBI-7092421;
CC       P67999; P67999: Rps6kb1; NbExp=2; IntAct=EBI-2639458, EBI-2639458;
CC       P67999; Q8N122: RPTOR; Xeno; NbExp=2; IntAct=EBI-2639458, EBI-1567928;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Synapse, synaptosome. Mitochondrion
CC       outer membrane. Mitochondrion {ECO:0000250}. Note=Colocalizes with URI1
CC       at mitochondrion. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=Alpha I;
CC         IsoId=P67999-1; Sequence=Displayed;
CC       Name=Alpha II;
CC         IsoId=P67999-2; Sequence=VSP_018842;
CC   -!- TISSUE SPECIFICITY: Brain.
CC   -!- DOMAIN: The autoinhibitory domain is believed to block phosphorylation
CC       within the AGC-kinase C-terminal domain and the activation loop.
CC   -!- DOMAIN: The TOS (TOR signaling) motif is essential for activation by
CC       mTORC1.
CC   -!- PTM: Dephosphorylation by PPP1CC at Thr-412 in mitochondrion (By
CC       similarity). Phosphorylation at Thr-412 is regulated by mTORC1. The
CC       phosphorylation at this site is maintained by an agonist-dependent
CC       autophosphorylation mechanism. Activated by phosphorylation at Thr-252
CC       by PDPK1. {ECO:0000250, ECO:0000269|PubMed:11516946,
CC       ECO:0000269|PubMed:9465032, ECO:0000269|PubMed:9632736}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M58340; AAA42104.1; -; mRNA.
DR   EMBL; M57428; AAA42103.1; -; mRNA.
DR   PIR; A36484; TVRTK6.
DR   RefSeq; NP_114191.1; NM_031985.1.
DR   AlphaFoldDB; P67999; -.
DR   SMR; P67999; -.
DR   BioGRID; 249866; 3.
DR   ELM; P67999; -.
DR   IntAct; P67999; 6.
DR   MINT; P67999; -.
DR   STRING; 10116.ENSRNOP00000005226; -.
DR   GlyGen; P67999; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P67999; -.
DR   PhosphoSitePlus; P67999; -.
DR   jPOST; P67999; -.
DR   PaxDb; 10116-ENSRNOP00000005226; -.
DR   Ensembl; ENSRNOT00000118202.1; ENSRNOP00000078345.1; ENSRNOG00000003919.6. [P67999-1]
DR   Ensembl; ENSRNOT00055053033; ENSRNOP00055043833; ENSRNOG00055030559. [P67999-1]
DR   Ensembl; ENSRNOT00060033822; ENSRNOP00060027706; ENSRNOG00060019524. [P67999-1]
DR   Ensembl; ENSRNOT00065030367; ENSRNOP00065024144; ENSRNOG00065018112. [P67999-1]
DR   GeneID; 83840; -.
DR   KEGG; rno:83840; -.
DR   AGR; RGD:620683; -.
DR   CTD; 6198; -.
DR   RGD; 620683; Rps6kb1.
DR   eggNOG; KOG0598; Eukaryota.
DR   GeneTree; ENSGT00940000154203; -.
DR   HOGENOM; CLU_000288_63_5_1; -.
DR   InParanoid; P67999; -.
DR   OMA; CWTAMPP; -.
DR   OrthoDB; 5489497at2759; -.
DR   PhylomeDB; P67999; -.
DR   TreeFam; TF313438; -.
DR   BRENDA; 2.7.11.1; 5301.
DR   Reactome; R-RNO-166208; mTORC1-mediated signalling.
DR   SABIO-RK; P67999; -.
DR   PRO; PR:P67999; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Bgee; ENSRNOG00000003919; Expressed in quadriceps femoris and 20 other cell types or tissues.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IEA:UniProtKB-KW.
DR   GO; GO:0005654; C:nucleoplasm; IBA:GO_Central.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:RGD.
DR   GO; GO:0098794; C:postsynapse; IDA:SynGO.
DR   GO; GO:0045202; C:synapse; IDA:SynGO.
DR   GO; GO:0005524; F:ATP binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:RGD.
DR   GO; GO:0042277; F:peptide binding; IDA:RGD.
DR   GO; GO:0004672; F:protein kinase activity; IDA:RGD.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IPI:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISO:RGD.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; ISO:RGD.
DR   GO; GO:0004711; F:ribosomal protein S6 kinase activity; IMP:RGD.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0001662; P:behavioral fear response; ISO:RGD.
DR   GO; GO:0016477; P:cell migration; IEP:RGD.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; ISO:RGD.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IEP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISO:RGD.
DR   GO; GO:0031670; P:cellular response to nutrient; ISO:RGD.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; ISO:RGD.
DR   GO; GO:0071346; P:cellular response to type II interferon; ISO:RGD.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; ISO:RGD.
DR   GO; GO:0007281; P:germ cell development; ISO:RGD.
DR   GO; GO:0044539; P:long-chain fatty acid import into cell; ISS:UniProtKB.
DR   GO; GO:0007616; P:long-term memory; IEP:RGD.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:RGD.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISO:RGD.
DR   GO; GO:0048633; P:positive regulation of skeletal muscle tissue growth; IMP:RGD.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:RGD.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:1904263; P:positive regulation of TORC1 signaling; ISO:RGD.
DR   GO; GO:0045727; P:positive regulation of translation; ISO:RGD.
DR   GO; GO:0045948; P:positive regulation of translational initiation; ISO:RGD.
DR   GO; GO:0046324; P:regulation of glucose import; IMP:UniProtKB.
DR   GO; GO:0043200; P:response to amino acid; IEP:RGD.
DR   GO; GO:0014878; P:response to electrical stimulus involved in regulation of muscle adaptation; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0033762; P:response to glucagon; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0009749; P:response to glucose; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IMP:UniProtKB.
DR   GO; GO:0043201; P:response to L-leucine; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0007584; P:response to nutrient; IEP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; ISO:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0043434; P:response to peptide hormone; IEP:RGD.
DR   GO; GO:0033574; P:response to testosterone; IEP:RGD.
DR   GO; GO:0009636; P:response to toxic substance; IEP:RGD.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IMP:UniProtKB.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0014732; P:skeletal muscle atrophy; IEP:RGD.
DR   GO; GO:0003009; P:skeletal muscle contraction; IEP:RGD.
DR   GO; GO:0031929; P:TOR signaling; ISS:UniProtKB.
DR   CDD; cd05584; STKc_p70S6K; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016238; Ribosomal_S6_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1.
DR   PANTHER; PTHR24351:SF48; RIBOSOMAL PROTEIN S6 KINASE BETA-1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000605; Ribsml_S6_kin_1; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative initiation; Apoptosis; ATP-binding; Cell cycle;
KW   Cytoplasm; Direct protein sequencing; Kinase; Membrane; Mitochondrion;
KW   Mitochondrion outer membrane; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Synapse; Synaptosome;
KW   Transferase; Translation regulation.
FT   CHAIN           1..525
FT                   /note="Ribosomal protein S6 kinase beta-1"
FT                   /id="PRO_0000024348"
FT   DOMAIN          91..352
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          353..423
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   REGION          28..54
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          380..399
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          424..525
FT                   /note="Autoinhibitory domain"
FT   REGION          486..509
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           28..32
FT                   /note="TOS motif"
FT   COMPBIAS        28..48
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        218
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         97..105
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         123
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         252
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000269|PubMed:9632736"
FT   MOD_RES         394
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:9632736"
FT   MOD_RES         412
FT                   /note="Phosphothreonine; by MTOR, NEK6 and NEK7"
FT                   /evidence="ECO:0000269|PubMed:11516946,
FT                   ECO:0000269|PubMed:9465032, ECO:0000269|PubMed:9632736"
FT   MOD_RES         434
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:9632736"
FT   MOD_RES         441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P23443"
FT   MOD_RES         444
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:9632736"
FT   MOD_RES         447
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:9632736,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         516
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20599721"
FT   VAR_SEQ         1..23
FT                   /note="Missing (in isoform Alpha II)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_018842"
FT   MUTAGEN         28..32
FT                   /note="Missing: Almost complete loss of activity."
FT                   /evidence="ECO:0000269|PubMed:9653190"
FT   MUTAGEN         28
FT                   /note="F->A: Complete loss of activity. Abolishes
FT                   interaction with RPTOR. Reduces phosphorylation. Loss of
FT                   phosphorylation at T-412 and T-444."
FT                   /evidence="ECO:0000269|PubMed:11967149,
FT                   ECO:0000269|PubMed:12604610"
FT   MUTAGEN         29
FT                   /note="D->A: Almost complete loss of activity; when
FT                   associated with A-31."
FT                   /evidence="ECO:0000269|PubMed:11967149"
FT   MUTAGEN         30
FT                   /note="I->A: Almost complete loss of activity; when
FT                   associated with A-32."
FT                   /evidence="ECO:0000269|PubMed:11967149"
FT   MUTAGEN         31
FT                   /note="D->A: Almost complete loss of activity; when
FT                   associated with A-29."
FT                   /evidence="ECO:0000269|PubMed:11967149"
FT   MUTAGEN         32
FT                   /note="L->A: Almost complete loss of activity; when
FT                   associated with A-30."
FT                   /evidence="ECO:0000269|PubMed:11967149"
FT   MUTAGEN         123
FT                   /note="K->M: Loss of activity towards ribosomal protein
FT                   S6."
FT                   /evidence="ECO:0000269|PubMed:8524831,
FT                   ECO:0000269|PubMed:9632736"
FT   MUTAGEN         123
FT                   /note="K->R: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:8524831,
FT                   ECO:0000269|PubMed:9632736"
FT   MUTAGEN         252
FT                   /note="T->A: Loss of activity towards ribosomal protein S6
FT                   and reduced phosphorylation at Thr-412."
FT                   /evidence="ECO:0000269|PubMed:9632736"
FT   MUTAGEN         256
FT                   /note="T->A: Loss of activity towards ribosomal protein S6
FT                   without effect on phosphorylation status."
FT                   /evidence="ECO:0000269|PubMed:9632736"
FT   MUTAGEN         394
FT                   /note="S->A,D: Loss of activity towards ribosomal protein
FT                   S6 and reduces phosphorylation at Thr-252."
FT                   /evidence="ECO:0000269|PubMed:9632736"
FT   MUTAGEN         412
FT                   /note="T->A: Loss of activity towards ribosomal protein S6
FT                   and loss of phosphorylation at Thr-252."
FT                   /evidence="ECO:0000269|PubMed:9632736"
FT   MUTAGEN         412
FT                   /note="T->E: Mimics phosphorylation. Constitutive active.
FT                   No effect on activity towards ribosomal protein S6."
FT                   /evidence="ECO:0000269|PubMed:9632736"
FT   MUTAGEN         434
FT                   /note="S->D: No effect on sensitivity to wortmannin and
FT                   rapamycin; when associated with D-441, D-444 and D-447."
FT                   /evidence="ECO:0000269|PubMed:8524831"
FT   MUTAGEN         441
FT                   /note="S->D: No effect on sensitivity to wortmannin and
FT                   rapamycin; when associated with D-434, D-D-444 and D-447."
FT                   /evidence="ECO:0000269|PubMed:8524831"
FT   MUTAGEN         444
FT                   /note="T->D: No effect on sensitivity to wortmannin and
FT                   rapamycin; when associated with D-434, D-441, and D-447."
FT                   /evidence="ECO:0000269|PubMed:8524831"
FT   MUTAGEN         447
FT                   /note="S->D: No effect on sensitivity to wortmannin and
FT                   rapamycin; when associated with D-434, D-441 and D-444."
FT                   /evidence="ECO:0000269|PubMed:8524831"
FT   CONFLICT        367
FT                   /note="P -> R (in Ref. 1; AAA42104)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   525 AA;  59132 MW;  013BA13EFB3508D7 CRC64;
     MRRRRRRDGF YPAPDFRHRE AEDMAGVFDI DLDQPEDAGS EDELEEGGQL NESMDHGGVG
     PYELGMEHCE KFEISETSVN RGPEKIRPEC FELLRVLGKG GYGKVFQVRK VTGANTGKIF
     AMKVLKKAMI VRNAKDTAHT KAERNILEEV KHPFIVDLIY AFQTGGKLYL ILEYLSGGEL
     FMQLEREGIF MEDTACFYLA EISMALGHLH QKGIIYRDLK PENIMLNHQG HVKLTDFGLC
     KESIHDGTVT HTFCGTIEYM APEILMRSGH NRAVDWWSLG ALMYDMLTGA PPFTGENRKK
     TIDKILKCKL NLPPYLTQEA RDLLKKLLKR NAASRLGAGP GDAGEVQAHP FFRHINWEEL
     LARKVEPPFK PLLQSEEDVS QFDSKFTRQT PVDSPDDSTL SESANQVFLG FTYVAPSVLE
     SVKEKFSFEP KIRSPRRFIG SPRTPVSPVK FSPGDFWGRG ASASTANPQT PVEYPMETSG
     IEQMDVTTSG EASAPLPIRQ PNSGPYKKQA FPMISKRPEH LRMNL
//
